BiondVax – executive interview

BiondVax – executive interview

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercialising innovative products for the prevention and treatment of infectious diseases and other illnesses. It is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases such as COVID-19, asthma and psoriasis.

In this interview, Elad Mark, BiondVax’s chief operating officer, discusses the company’s GMP biologics manufacturing facility and its suitability for the new NanoAb pipeline.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free